Full Text:   <1196>

CLC number: R730.2

On-line Access: 2020-01-03

Received: 2019-12-16

Revision Accepted: 2019-12-16

Crosschecked: 2019-06-23

Cited: 0

Clicked: 2096

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2020 Vol.21 No.1 P.1-2

http://doi.org/10.1631/jzus.B1910003


Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology


Author(s):  Xinguo Jiang

Affiliation(s):  VA Palo Alto Health Care System, Stanford University School of Medicine, Palo Alto, CA 94304, USA

Corresponding email(s):   xinguoj@stanford.edu

Key Words:  Lymphatic, MicroRNA, Chimera antigen receptor T cell, Immunology, Immune therapy


Share this article to: More |Next Article >>>

Xinguo Jiang. Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology[J]. Journal of Zhejiang University Science B, 2020, 21(1): 1-2.

@article{title="Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology",
author="Xinguo Jiang",
journal="Journal of Zhejiang University Science B",
volume="21",
number="1",
pages="1-2",
year="2020",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1910003"
}

%0 Journal Article
%T Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology
%A Xinguo Jiang
%J Journal of Zhejiang University SCIENCE B
%V 21
%N 1
%P 1-2
%@ 1673-1581
%D 2020
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1910003

TY - JOUR
T1 - Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology
A1 - Xinguo Jiang
J0 - Journal of Zhejiang University Science B
VL - 21
IS - 1
SP - 1
EP - 2
%@ 1673-1581
Y1 - 2020
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1910003


Abstract: 
This special feature contains three review articles that summarize recent advances pertaining to tumor immunobiology. Normalization of antitumor immunity through checkpoint inhibitors has achieved significant clinical success and benefited many cancer patients. However, not all cancer patients respond to these treatments, and among the responders, some may develop resistance and others may suffer autoimmunity that requires intervention. Tumor immunotherapy holds promise for further improving the survival of cancer patients, but deeper understanding of immunological networks that regulate anti- and pro-tumor immunity is needed. The review papers collected in this issue cover a few topics that may stimulate future interest in the relevant research field.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Chen C, Liu JM, Luo YP, 2020. MicroRNAs in tumor immunity: functional regulation in tumor-associated macrophages. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):12-28.

[2]Huang H, Wu HW, Hu YX, 2020. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):29-41.

[3]Jiang X, 2020. Lymphatic vasculature in tumor metastasis and immunobiology. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 21(1):3-11.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE